Benutzer: Gast  Login
Titel:

Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer.

Dokumenttyp:
Journal Article
Autor(en):
Escudier, Bernard; Grünwald, Viktor; Ravaud, Alain; Ou, Yen-Chuan; Castellano, Daniel; Lin, Chia-Chi; Gschwend, Jürgen E; Harzstark, Andrea; Beall, Sarah; Pirotta, Nicoletta; Squires, Matthew; Shi, Michael M; Angevin, Eric
Abstract:
Fibroblast growth factor (FGF) signaling regulates tumor growth and vascularization and partly mediates antiangiogenic escape from VEGF receptor (VEGFR) inhibitors. Dovitinib (TKI258) is a tyrosine kinase inhibitor (TKI) that inhibits FGF receptor (FGFR), VEGFR, and platelet-derived growth factor receptor, which are known drivers of antiangiogenic escape, angiogenesis, and tumor growth in renal cell carcinoma (RCC).Patients with advanced or metastatic RCC were treated with oral dovitinib 500 mg/...     »
Zeitschriftentitel:
Clin Cancer Res
Jahr:
2014
Band / Volume:
20
Heft / Issue:
11
Seitenangaben Beitrag:
3012-22
Sprache:
eng
Volltext / DOI:
doi:10.1158/1078-0432.CCR-13-3006
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/24691021
Print-ISSN:
1078-0432
TUM Einrichtung:
Urologische Klinik und Poliklinik
 BibTeX